0
Il n'y a pas de produit dans le panier !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Accueil > GITR

GITR

Brief Information

Name:Glucocorticoid-induced tumor necrosis factor receptor-related protein
Target Synonym:TNFRSF18,TNF Receptor Superfamily Activation-Inducible Protein,ENERGEN,GITR-D,Tumor Necrosis Factor Receptor Superfamily Member 18,CD357 Antigen,Activation-Inducible TNFR Family Receptor,AITR,CD357,GITR,Glucocorticoid-Induced TNFR-Related Protein,Tumor Necrosis Factor Receptor Superfamily, Member 18,TNF Receptor Superfamily Member 18
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:8
Lastest Research Phase:Phase 2 Clinical

Product ListCompare or Buy

ACRO Quality

Part of Bioactivity data

GIR-H82E1-ELISA
 GITR ELISA

Immobilized Human GITR Ligand, Fc Tag at 10 μg/mL (100 μL/well) can bind Biotinylated Human GITR, His,Avi tag™ (Cat. No. GIR-H82E1) with a linear range of 0.039-0.625 μg/mL (QC tested).

GIR-H82E1-MALS-HPLC
GITR MALS images

The purity of Biotinylated Human GITR Protein, His,Avitag (Cat. No. GIR-H82E1) is more than 95% and the molecular weight of this protein is around 20-30 kDa verified by SEC-MALS.

Customer Reviews

Synonym Name

AITR,GITR,TNFRSF18,CD357

Background

Glucocorticoid-induced TNFR-related protein (GITR) is also known as Tumor necrosis factor receptor superfamily member 18 (TNFRSF18), activation-inducible TNFR family receptor (AITR), CD antigen CD357, which is a member of the tumor necrosis factor receptor (TNF-R) superfamily. GITR is receptor for TNFSF18, which seems to be involved in interactions between activated T-lymphocytes and endothelial cells and in the regulation of T-cell receptor-mediated cell death. GITR also mediated NF-kappa-B activation via the TRAF2/NIK pathway.

Clinical and Translational Updates

Related Molecule

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
BMS-986156 BMS-986156 Phase 2 Clinical Bristol-Myers Squibb Company Solid tumours; Liver Neoplasms; Thoracic Neoplasms; Neoplasms; Lung Neoplasms Details
Ragifilimab INCAGN-1876; INCAGN-01876; AGEN-1876; CM-701 Phase 2 Clinical Agenus Inc, Ludwig Institute For Cancer Research Neoplasms; Neoplasm Metastasis Details
Anti-GITR antibody (BMS) Phase 1 Clinical Bristol-Myers Squibb Company Neoplasms Details
LY-3844583 LY-3844583; LY3844583 Phase 1 Clinical Eli Lilly And Company Dermatitis, Atopic Details
REGN-6569 REGN-6569; REGN6569 Phase 1 Clinical Squamous Cell Carcinoma of Head and Neck Details
GWN-323 GWN-323 Phase 1 Clinical Novartis Pharma Ag Solid tumours; Lymphoma Details
MK-4166 MK-4166 Phase 1 Clinical Merck & Co Inc Solid tumours Details
BMS-986156 BMS-986156 Phase 2 Clinical Bristol-Myers Squibb Company Solid tumours; Liver Neoplasms; Thoracic Neoplasms; Neoplasms; Lung Neoplasms Details
Ragifilimab INCAGN-1876; INCAGN-01876; AGEN-1876; CM-701 Phase 2 Clinical Agenus Inc, Ludwig Institute For Cancer Research Neoplasms; Neoplasm Metastasis Details
Anti-GITR antibody (BMS) Phase 1 Clinical Bristol-Myers Squibb Company Neoplasms Details
LY-3844583 LY-3844583; LY3844583 Phase 1 Clinical Eli Lilly And Company Dermatitis, Atopic Details
REGN-6569 REGN-6569; REGN6569 Phase 1 Clinical Squamous Cell Carcinoma of Head and Neck Details
GWN-323 GWN-323 Phase 1 Clinical Novartis Pharma Ag Solid tumours; Lymphoma Details
MK-4166 MK-4166 Phase 1 Clinical Merck & Co Inc Solid tumours Details

This web search service is supported by Google Inc.

totop

Laisser un message